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Abstract
Background: Neurofibromatosis type 1 is an autosomal dominant neurocutaneous disorder with
characteristic features of skin and central nervous system involvement. Gastrointestinal
involvement is rare, but the risk of malignancy development is considerable. Zollinger-Ellison
syndrome is caused by gastrin-secreting tumors called gastrinomas. Correct diagnosis is often
difficult, and curative treatment can only be achieved surgically.
Case presentation: A 41-year-old female affected by neurofibromatosis type 1 presented with a
history of recurrent epigastric soreness, diarrhea, and relapsing chronic duodenal ulcer. Her serum
fasting gastrin level was over 1000 pg/mL. An abdominal CT scan revealed a 3 × 2-cm, well-
enhanced mass adjacent to the duodenal loop. She was not associated with multiple endocrine
neoplasia type 1. Operative resection was performed and gastrinoma was diagnosed by
immunohistochemical staining. The serum gastrin level decreased to 99.1 pg/mL after surgery, and
symptoms and endoscopic findings completely resolved without recurrences.
Conclusion: Gastrinoma is difficult to detect even in the general population, and hence symptoms
such as recurrent idiopathic peptic ulcer and diarrhea in neurofibromatosis type 1 patients should
be accounted for as possibly contributing to Zollinger-Ellison syndrome.
Background
Neurofibromatosis type 1 (NF1) is an autosomal domi-
nant neurocutaneous disorder with an estimated preva-
lence of 2 to 3 cases per 10,000 population [1]. NF1 is
characterized by neurocutaneous signs such as café-au-lait
spots, axillary freckling, and cutaneous neurofibromas.
Cognitive deficits and academic learning difficulties are
the most common neurological complications of NF1 in
childhood. Moreover, patients with NF1 are at an
increased risk of developing nervous system neoplasms.
Malignancy other than of nervous system origin can
develop, with the prevalence of such malignant tumors
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reportedly being four times higher in NF1 patients than in
the general population [2]. Gastrointestinal malignancy
was reported to be associated with NF1 patients, with neu-
roendocrine tumors being the most prevalent [3]. How-
ever, there have been only one report about gastrinoma
associated with NF1.
Zollinger-Ellison syndrome (ZES) is characterized by
hypersecretion of gastrin from a gastrinoma that leads to
gastric acid hypersecretion and, most notably, clinical
symptoms of refractory peptic ulcer disease. Zollinger and
Ellison were the first to report recurrent peptic ulcers of
the jejunum associated with nonbeta islet cell tumors of
Abdominal CT scan showing a 3 × 2 cm, well-defined, uniformly enhanced mass adjacent to the duodenal loop Figure 1
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the pancreas [4]. The diagnosis is based on a combination
of criteria, including clinical presentation, serum gastrin
level, acid-secretion test, and diagnostic imaging studies.
Improvements in medical management using proton-
pump inhibitors mean that gastric acid hypersecretion can
be effectively controlled in most cases. Determining the
presence of metastasis to regional lymph nodes or the
liver to monitor malignant progression is important
before definitive treatment. ZES in the form of multiple
endocrine neoplasia type 1 (MEN1) needs special consid-
eration, since the disease progression, presentation, and
treatment differ from those in the sporadic form [5].
In this report, we describe a patient with NF1 who was
diagnosed as ZES and successfully treated by curative
surgery.
Case presentation
A 41-year-old female NF1 patient was admitted for the
evaluation of a 3-year history of recurrent epigastric sore-
ness, heartburn, and diarrhea. Repeated endoscopic
examinations revealed recurrent duodenal ulcers. The
symptoms were relieved by proton-pump inhibitors, but
recurred when the medication was withdrawn. She was
previously diagnosed with NF1 based on clinical features
and family history. Her first-degree relatives (i.e., brother,
sister, and second son) were also affected by fully devel-
oped features of NF1. She had no cognitive dysfunction or
learning disabilities, and showed normal intellectual
development. A physical examination revealed several
café-au-lait spots and multiple small nodules on the ante-
rior chest and areolar area, and also multiple axillary
freckles. A skin-nodule biopsy demonstrated characteris-
tic neurofibromas.
The pathologic findings were of a well-encapsulated solid mass containing cells with a diffuse, trabecular growth pattern Figure 2
The pathologic findings were of a well-encapsulated solid mass containing cells with a diffuse, trabecular growth pattern. (×40, 
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On admission, upper gastrointestinal endoscopy revealed
multiple shallow ulcers in the descending duodenum. The
rapid urease test and urea breath test for Helicobacter pylori
were both negative. The serum fasting gastrin level was
>1,000 pg/mL and 837 pg/mL in two consecutive meas-
urements. A secretin stimulation test was not performed
due to the unavailability of secretin. As a diagnosis of gas-
trinoma was strongly suggested, radiologic evaluations
were performed to locate the lesion. Abdominal com-
puted tomography (CT) and magnetic resonance imaging
(MRI) scans showed a 3 × 2-cm, clearly defined, well-
enhanced mass adjacent to the duodenal loop in the sub-
hepatic space (Figure 1). No metastatic lesions were
observed in the liver or regional lymph nodes.
The association with MEN1 status was evaluated by hor-
monal and radiologic investigations of the parathyroid,
pituitary, pancreas, and adrenal gland, which proved to be
negative. As a definitive treatment, an intraabdominal
mass of about 2.5 × 2 cm with a thick fibrous capsular
outer layer was surgically isolated and completely resected
from the right lateral border of the descending duode-
num. Gastrinoma was finally diagnosed by immunohisto-
chemical staining (Figures 2, 3). An incidental finding
during the operation was numerous, small (<1.0 cm),
whitish nodular masses on the serosal surface of the small
bowel, many of which were enucleated. The pathologic
diagnosis was gastrointestinal stromal tumor (GIST) with
a low mitotic index as evidenced by C-kit positivity (Fig-
ures 4, 5). The serum gastrin level decreased markedly to
The tumor cells were strongly immunopositive for gastrin Figure 3
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99.1 pg/mL at 1 month after the operation, and to 53.2
pg/mL 3 months later. There were no symptomatic or
radiologic recurrences during a 14-month follow up.
Discussion
NF1 is an autosomal dominant single-gene disorder with
an estimated prevalence of 2 to 3 cases per 10,000 popu-
lation [1]. NF1 is characterized by neurocutaneous signs,
such as café-au-lait spots, axillary freckling, and cutaneous
neurofibromatosis, and iris hamartomas [6]. Neurofibro-
mas are benign peripheral nerve tumors composed of pro-
liferating Schwann cells and fibroblasts. They present as
multiple palpable, rubbery cutaneous tumors, and are
generally asymptomatic.
In our case, the diagnosis of NF1 was established based on
characteristic clinical features including dermatologic
findings, pathological diagnosis of neurofibroma, and
familial history of NF1 in first-degree relatives. These ful-
filled the diagnostic criteria of NF1, and so further genetic
testing was considered unnecessary [6]. There was a possi-
bility that the skin lesions were associated with the MEN1
and that the gastrinoma occurred in the context of MEN1.
However, meticulous laboratory and radiologic investiga-
tions indicated that the patient was not affected by MEN1.
NF1 patients have mutations of the NF1 gene on chromo-
some 17 [7]. The NF1 gene is a tumor-suppressor gene
encoding a protein, neurofibromin, which functions in
normal cells as a suppressor of the ras signaling cascades
[8].
The development of malignancy in NF1 is frequently
encountered, and can influence the outcome [9]. The
prevalence of malignant tumors is reportedly four times
higher in NF1 patients than in the general population [2].
Biopsy of the multiple small nodules revealed the haphazard arrangement of uniform spindle cells in a collagenous stroma Figure 4
Biopsy of the multiple small nodules revealed the haphazard arrangement of uniform spindle cells in a collagenous stroma. 
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Patients with NF1 are at an increased risk of developing
central nervous system tumors, including optic pathway
gliomas and brainstem and cerebellar tumors [10,11].
Gastrointestinal involvement in NF1 occurs at diverse
locations, and its clinical features encompass variable
manifestations including intestinal bleeding, ischemia,
angina, infarction, and bowel obstruction [12-16]. A pre-
vious report suggested that gastrointestinal involvement
in NF1 occurs as intestinal ganglioneuromas, GISTs, and
carcinoids of the periampullary region of the duodenum
that may be associated with pheochromocytoma [3].
Several cases of gastrointestinal adenocarcinomas have
been reported in literature [17,18], but the most common
gastrointestinal malignancy in NF1 is neuroendocrine
tumors in the upper gastrointestinal tract, characteristi-
cally in the periampullary region [19-21]. Many are classi-
fied as somatostatinomas [22,23], and NF1 has rarely
been associated with insulinomas and gastrinomas
[24,25]. Our literature review revealed only one reported
case of ZES associated with NF1, and hence the present
case represents only the second reported case. The multi-
ple small nodular tumors attached to the serosal surface of
the small bowel observed during laparotomy in our
patient were found to be stromal tumors with a low malig-
nant potential. We assumed that these stromal tumors
were an incidental finding that carried no current poten-
tial risk of developing into malignant GIST.
Most patients with ZES initially present with abdominal
pain, heartburn, diarrhea, and weight loss. These patients
are often misdiagnosed as idiopathic peptic ulcer disease,
resulting in a delayed true diagnosis that leads to a more
advanced stage of the disease.
The diagnosis of ZES is based on previously described cri-
teria [26]. A fasting serum gastrin level of >200 pg/mL
should raise the suspicion of the disease, and a level of
>1000 pg/mL without the presence of achlorhydria sec-
ondary to atrophic gastritis is virtually indicative of ZES.
Gastric secretory testing usually demonstrates the
The tumor cells were immunopositive for C-kit (CD117) Figure 5
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presence of a basal acid output of greater than 15 mEq in
unoperated patients. The secretin stimulation test is a
useful way to confirm the diagnosis of ZES (where the
increase is >200 pg/mL), when the fasting serum gastrin
level is only modestly elevated and the diagnosis is in
doubt [27]. Finally, a positive histologic confirmation of
gastrinoma provides definitive evidence of the presence of
ZES. In our case, an elevated level of gastrin and character-
istic pathologic findings indicated the correct diagnosis of
ZES.
More than 80% of the tumors in ZES are located in the so-
called gastrinoma triangle [28]. In addition, more than
90% of duodenal gastrinomas occur in the first or second
portion of the duodenum, and about 50% of them are sol-
itary [29]. In our case, the tumor was located in the
extraduodenal space within the gastrinoma triangle.
Various imaging methods are available for localizing a
gastrinoma. In our patient, the tumor was detected by
conventional CT and MRI scans as a isolated, well-con-
tained mass without metastasis to the liver or lymph
nodes, which enabled curative resection.
Conclusion
Most patients with NF1 never develop major complica-
tions, but the mainstay of care remains anticipatory
guidance and surveillance for treatable complications. As
in our case, NF1 can be related to neuroendocrine tumors
that will progress if not managed early in the course of the
disease. As accurate diagnosis of gastrinoma can be diffi-
cult, a high level of suspicion and timely evaluation
should be applied to NF1 patients manifesting character-
istic symptoms attributable to ZES.
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